P

    Protara Therapeutics Inc (TARA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.86
    +0.04 (+1.05%)

    Market Cap: $225.75M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(23/40)
    Avg Surprise
    -22.69%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.33
    Range$-0.38 - $-0.26
    7 analysts
    EPS Revisions
    4
    0
    7d
    4
    0
    30d
    EPS Estimate Drift
    90d ago$-0.38-14.6%
    60d ago$-0.38-16.1%
    30d ago$-0.34-3.1%
    7d ago$-0.33+1.0%
    Current$-0.33
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    Dec 31, 2026
    EPS Consensus$-0.38
    Range$-0.45 - $-0.30
    6 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.38---
    Sep 26EST
    		-$-0.33---
    Jun 26
    		$-0.36$-0.33-9.09%Miss-2.9%
    Mar 26
    		$-0.31$-0.37+16.22%Beat-6.9%
    Dec 25
    		$-0.38$-0.31-21.79%Miss+11.6%
    Sep 25
    		$-0.31$-0.38+18.42%Beat+38.0%
    Jun 25
    		$-0.35$-0.41+14.63%Beat+22.2%
    Mar 25
    		$-0.29$-0.48+39.58%Beat+70.1%
    Dec 24
    		$-0.43$-0.56+23.89%Beat+52.2%
    Sep 24
    		$-0.50$-0.52+3.85%Beat+42.5%
    Jun 24
    		$-0.45$-0.74+39.19%Beat+55.0%
    Mar 24
    		$-0.97$-0.92-5.43%Miss-21.2%
    Dec 23
    		$-0.90$-0.92+2.17%Beat+41.9%
    Sep 23
    		$-0.87$-0.98+11.22%Beat-27.9%
    Jun 23
    		$-1.00$-0.94-6.38%Miss-25.0%
    Mar 23
    		$-0.80$-0.87+8.05%Beat+16.7%
    Dec 22
    		$-1.55$-0.75-106.67%Miss-70.3%
    Sep 22
    		$-0.68$-0.70+2.86%Beat+29.2%
    Jun 22
    		$-0.80$-0.78-2.56%Miss+29.8%
    Mar 22
    		$-0.96$-0.77-24.68%Miss+20.0%
    Dec 21
    		$-0.91$-0.94+3.19%Beat-106.8%
    Sep 21
    		$-0.96$-0.96+0.00%Beat+23.8%
    Jun 21
    		$-1.14$-0.96-18.75%Miss+6.6%
    Mar 21
    		$-1.20$-0.63-90.48%Miss+33.7%
    Dec 20
    		$-0.44$-0.54+18.52%Beat+82.7%
    Sep 20
    		$-1.26$-0.62-103.23%Miss+60.6%
    Jun 20
    		$-1.22$-0.83-46.99%Miss+88.7%
    Mar 20
    		$-1.81$-0.41-341.46%Miss+86.7%
    Dec 19
    		$-2.55$-0.71-259.15%Miss+76.4%
    Sep 19
    		$-3.20$-3.60+11.11%Beat+68.0%
    Jun 19
    		$-10.80$-6.80-58.82%Miss+3.6%
    Mar 19
    		$-13.60$-9.00-51.11%Miss+0.0%
    Dec 18
    		$-10.80$-10.20-5.88%Miss+12.9%
    Sep 18
    		$-10.00$-12.00+16.67%Beat+64.3%
    Jun 18
    		$-11.20$-14.20+21.13%Beat+15.2%
    Mar 18
    		$-13.60$-13.84+1.73%Beat+12.8%
    Dec 17
    		$-12.40$-16.80+26.19%Beat+26.2%
    Sep 17
    		$-28.00$-15.53-80.30%Miss-62.8%
    Jun 17
    		$-13.20$-17.20+23.26%Beat-
    Mar 17
    		$-15.60$-16.70+6.59%Beat-
    Dec 16
    		$-16.80$-18.30+8.20%Beat-
    Sep 16
    		$-17.20$-18.80+8.51%Beat-

    Key Metrics

    Valuation
    P/E Ratio-2.84EV/EBITDA0.74x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-45.80%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio10.97xQuick Ratio10.97x
    Trading Statistics
    Beta1.49Avg Volume372.32K
    52-Week High$7.8252-Week Low$3.02

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.91
    SMA 20$3.96
    SMA 50$4.02
    SMA 200$5.16
    EMA 10$3.91
    EMA 20$3.94
    EMA 50$4.08
    EMA 200$4.59

    MACD

    Line: -0.05Signal: -0.04Hist: -0.00

    ADX

    ADX: 15.8+DI: 14.0-DI: 23.7

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down80.0
    PSAR$4.08

    Bollinger Bands

    Upper Band$4.13
    Lower Band$3.79
    %B Position859%(Upper)
    Band Width0.21

    RSI (14-Day)

    Neutral
    43.9

    Momentum Oscillators

    Stoch %K41.0
    Stoch %D45.6
    Williams %R-63.8
    ROC (10d)-3.0%
    Momentum-0.12
    CCI (20d)-136.2
    MFI (14d)50.8

    Volatility Measures

    ATR (14d)$0.17(4.3%)
    StdDev (20d)0.09
    Hist Vol30.6%(Moderate)

    Volume Flow

    VWAP$3.82
    OBV-16.8M
    AD Line-16.6M
    CMF (20d)-0.010

    Volume Metrics

    Avg Vol (20d)378.9K
    Vol Ratio1.3x
    VWMA (20d)$3.95

    Pivot Points

    R3$4.15
    R2$4.07
    R1$3.94
    Pivot Point$3.87
    S1$3.74
    S2$3.66
    S3$3.54

    Advanced Oscillators

    TSI-9.90
    Ultimate Osc53.2
    KST-31.28

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$332,000$0$0$0$1.21M$0
    Cost of Revenue$0$0$93,000$0$0$0N/A$0$0$0$107,000$0
    Gross Profit$0$0$-93,000$0$0$0$166,000$0$0$0$1.10M$0
    Operating Expenses$23.32M$19.63M$19.08M$14.76M$16.59M$14.12M$14.31M$12.33M$10.66M$11.85M$11.04M$10.70M
    R&D$16.95M$13.56M$13.12M$9.59M$10.77M$9.15M$9.50M$8.07M$6.39M$7.75M$6.38M$6.22M
    SG&A$6.37M$6.07M$5.96M$5.17M$5.82M$4.98M$4.81M$4.26M$4.27M$4.10M$4.66M$4.48M
    Operating Income$-23,324,000$-19,629,000$-19,079,000$-14,760,000$-16,586,000$-14,124,000$-14,312,000$-12,330,000$-10,661,000$-11,851,000$-11,041,000$-10,700,000
    Interest Income$1.66M$1.85M$1.52M$1.50M$1.63M$1.73M$1.16M$1.11M$1.15M$756,000$820,000$840,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-21,668,000$-17,782,000$-17,307,000$-13,258,000$-14,960,000$-11,914,000$-12,769,000$-11,219,000$-9,513,000$-11,095,000$-10,221,000$-9,860,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-21,668,000$-17,782,000$-17,307,000$-13,258,000$-14,960,000$-11,914,000$-12,769,000$-11,219,000$-9,513,000$-11,095,000$-10,221,000$-9,860,000
    EBITDA$-23,252,000$-19,539,000$-19,054,000$-15,068,000$-16,854,000$-13,726,000$-14,122,000$-12,577,000$-10,585,000$-11,836,000$-11,047,000$-10,748,000
    EBIT$-23,324,000$-19,629,000$-18,830,000$-14,760,000$-16,586,000$-13,643,000$-13,925,000$-12,330,000$-10,661,000$-11,851,000$-11,041,000$-10,700,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TARA

    News

    Form 8K Protara Therapeutics Inc For: 11 August By Investing.com

    Protara Therapeutics Inc. has filed a Form 8K for August 11, as reported by Investing.com. The article includes the company's stock symbol TARA, which saw a -1.52% change, and allows users to view and post comments regarding the filing.

    Investing.com Nigeria•8/20/26•
    Neutral

    Assenagon Asset Management S.A. Sells 507,667 Shares of Protara Therapeutics, Inc. $TARA

    Assenagon Asset Management S.A. significantly reduced its stake in Protara Therapeutics (NASDAQ:TARA) by 89.4% in the second quarter, selling 507,667 shares and retaining 59,954 shares valued at $229,000. Despite this, other institutional investors like Geode Capital Management increased their positions, with overall institutional ownership at 38.13%. Protara Therapeutics opened at $3.97, and analysts maintain a "Moderate Buy" consensus with a target price of $26.25, even after the company reported a quarterly loss exceeding estimates.

    MarketBeat•8/17/26•
    Somewhat-Bearish

    Protara Therapeutics (NASDAQ:TARA) Downgraded to Strong Sell Rating by Wall Street Zen

    Wall Street Zen has downgraded Protara Therapeutics (NASDAQ:TARA) from a "sell" to a "strong sell" rating, despite a broader analyst consensus of "Moderate Buy" with an average price target of $26.25. The company's shares were trading at $3.97, near their 52-week low, after reporting a quarterly loss that missed estimates. Institutional ownership stands at 38.13%, with some firms, like Geode Capital Management, increasing their stakes.

    MarketBeat•8/15/26•
    Bearish

    Dimensional Fund Advisors LP Grows Stock Holdings in Protara Therapeutics, Inc. $TARA

    Dimensional Fund Advisors LP significantly increased its stake in Protara Therapeutics, Inc. (NASDAQ:TARA) by 133.9% in the first quarter, now holding over 531,000 shares valued at $2.77 million. Other institutional investors have also adjusted their holdings, with hedge funds and institutions collectively owning 38.13% of the stock. Despite missing earnings estimates in its latest quarterly report, Protara Therapeutics maintains a "Moderate Buy" consensus rating from analysts with an average price target of $26.25.

    MarketBeat•8/14/26•
    Neutral

    Janus Henderson Group (TARA holder) reports 8.4% Protara Therapeutics stake via Managed Portfolios

    Janus Henderson Group Ltd. has disclosed an 8.4% passive ownership stake in Protara Therapeutics, Inc. (TARA) through its asset managers, holding 4,696,709 shares of common stock. These shares are managed on behalf of client accounts, referred to as Managed Portfolios, with Janus Henderson exercising shared voting and dispositive power. The filing clarifies that while Janus Henderson Biotech Innovation Master Fund Ltd. holds the right to receive dividends or sale proceeds for over 5% of TARA's common stock, it is not considered a separate reporting person due to delegated investment and voting discretion.

    Stock Titan•8/13/26•
    Neutral

    Frequently Asked Questions About TARA

    Does TARA pay dividends?
    Protara Therapeutics Inc (TARA) does not currently pay a regular dividend.
    What is TARA's market cap?
    Protara Therapeutics Inc (TARA) has a market capitalization of $225.75M with a current stock price of $3.86.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In